TY - JOUR
T1 - Metabolic impairment in heart failure
T2 - The myocardial and systemic perspective
AU - Doehner, Wolfram
AU - Frenneaux, Michael
AU - Anker, Stefan D.
PY - 2014/9/30
Y1 - 2014/9/30
N2 - Although bioenergetic starvation is not a new concept in heart failure (HF), recent research has led to a growing appreciation of the complexity of metabolic aspects of HF pathophysiology. All steps of energy extraction, transfer, and utilization are affected, and structural metabolism is impaired, leading to compromised functional integrity of tissues. Not only the myocardium, but also peripheral tissues and organs are affected by metabolic failure, resulting in a global imbalance between catabolic and anabolic signals, leading to tissue wasting and, ultimately, to cachexia. Metabolic feedback signals from muscle and fat actively contribute to further myocardial strain, promoting disease progression. The prolonged survival of patients with stable, compensated HF will increasingly bring chronic metabolic complications of HF to the fore and gradually shift its clinical presentation. This paper reviews recent evidence on myocardial and systemic metabolic impairment in HF and summarizes current and emerging therapeutic concepts with specific metabolic targets.
AB - Although bioenergetic starvation is not a new concept in heart failure (HF), recent research has led to a growing appreciation of the complexity of metabolic aspects of HF pathophysiology. All steps of energy extraction, transfer, and utilization are affected, and structural metabolism is impaired, leading to compromised functional integrity of tissues. Not only the myocardium, but also peripheral tissues and organs are affected by metabolic failure, resulting in a global imbalance between catabolic and anabolic signals, leading to tissue wasting and, ultimately, to cachexia. Metabolic feedback signals from muscle and fat actively contribute to further myocardial strain, promoting disease progression. The prolonged survival of patients with stable, compensated HF will increasingly bring chronic metabolic complications of HF to the fore and gradually shift its clinical presentation. This paper reviews recent evidence on myocardial and systemic metabolic impairment in HF and summarizes current and emerging therapeutic concepts with specific metabolic targets.
KW - cachexia
KW - insulin resistance
KW - metabolism
KW - muscle
KW - sarcopenia
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=84908294192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908294192&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2014.04.083
DO - 10.1016/j.jacc.2014.04.083
M3 - Article
C2 - 25257642
AN - SCOPUS:84908294192
SN - 0735-1097
VL - 64
SP - 1388
EP - 1400
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 13
ER -